Find your ideal path to high-quality antibodies—our experts guide you to the best-fit discovery platform among hybridoma, phage display, single B cell, and AI-based technologies, tailored to your target, application and timeline.
Accelerate your therapeutic innovation with our comprehensive range of antibody and cell therapy solutions—from fully human and bispecific antibodies to CAR-T platforms, ADCs, and antibody humanization. Designed to support the development of next-generation therapeutics, our expert-guided services help you move faster toward clinical success.
As a diagnostic company, you deserve antibodies with outstanding specificity, sensitivity, and stability—fully compatible with assay formats like ELISA, rapid tests, and immunohistochemistry.
Whether you need antibodies or proteins to understand, detect, validate, or test your research, our 100% custom antibodies services, and off-the-shelf products are here to support your fundamental or translational studies.
Whether you’re developing novel biologics for livestock or companion animals, our platforms—phage display, hybridoma, and recombinant production—enable the generation of highly specific, stable, and species-adapted antibodies.
With proven expertise in veterinary targets and regulatory-grade deliverables, we support your path to safer, more effective animal therapies.
From gene synthesis to antibody bioproduction, our integrated services are designed to support your research at every step. Whether you’re just starting your project or scaling up for production, we provide tailored solutions to accelerate your progress and ensure continuity throughout your R&D journey. Tell us where you stand!
Founded in 2003, ProteoGenix is specialized in integrated solutions from gene to biotherapeutics and diagnostics. ProteoGenix is the trusted partner for pharmaceutical and biotech companies, CMOs and CDMOs seeking to develop custom assays and discover therapeutic antibodies. Our comprehensive suite of services includes:
From antigen design to hybridoma technology, phage display, and single B cell screening, we provide diverse and tailored approaches for generating high-quality antibodies.
We offer advanced antibody engineering services including humanization, affinity maturation, reformatting (e.g., bispecific antibodies, ADCs), and subtype or isotype switching.
Our expertise in recombinant monoclonal antibody production and stable cell line development ensures the reliable and scalable production of your therapeutic antibodies.
We offer protein expression across multiple systems, including E. coli, B. subtilis, yeast, insect cells, and mammalian cells, ensuring the right solution for your specific needs.
Tailored peptide synthesis services for your research and therapeutic development.
High-quality gene synthesis for your project requirements, from research to clinical applications.
Ensure confidence in your experiments with high-performance antibodies and proteins.
With a catalog of 15,000+ products, we provide reliable solutions to accelerate your research and drug development.
Get the right bioreagents, get faster results!
New
XtenCHO™ Race empowers researchers to produce the proteins they need—without the usual time and budget constraints.
With XtenCHO™ Race, achieve outstanding yields; reaching up to 1.8 g/L; and fast timelines, with harvest possible as early as day 8.
Get the ready-to-use kit for only 1950€
Research Area PD1-PDL1-PDL2
Discover antibodies capable of binding to either PD-1 or PD-L1, enabling the modulation of the immune response. This approach has been instrumental in developing cancer immunotherapies, as blocking the PD-1/PD-L1 interaction helps activate the body’s natural defense against cancer cells. Accelerate your research today!
Because progress takes more than just good science
Behind every promising therapeutic or diagnostic innovation lies a journey — complex, uncertain, and filled with critical decisions. To go from idea to impact, you don’t just need a vendor. You need the right partner.
At ProteoGenix, we exist to make that journey easier, smarter, and more successful — by combining deep scientific expertise with the power of technology, and by designing solutions that serve both science and ethics.
For 22+ years, ProteoGenix has proudly supported researchers worldwide in developing biotherapeutics and bio diagnostics. We cover every key stage of early-stage R&D — from discovery to engineering and production — offering seamless support with a single expert partner.
Based in US (North Carolina) and France, our global presence ensures fast and responsive service. Our experienced, customer-focused teams are committed to accelerating your projects and maximizing your chances of success.
At ProteoGenix, we see ourselves as committed partners in our clients’ research, contributing to the success of their projects through expertise and close collaboration. Whether the mission is short or long-term, we approach each one with the same dedication. Active listening and tailored solutions are at the heart of our approach.
Because risk is part of any research journey, we include GO/NO-GO milestones and offer success-based guarantees. Our ISO 9001 and ISO 14001 certifications reflect our strong commitment to quality, sustainability, and customer satisfaction.
Don’t miss the chance to meet our experts at key industry congresses. Stay ahead of the curve, discuss your projects, and explore new opportunities for collaboration.
Discover how researchers and industry leaders worldwide achieve success with our antibody solutions. Hear their stories and see the impact of our expertise on groundbreaking projects.
National Cancer Centre, Singapore
Prof Johnny Ong Chin-Ann, MD, PhD, Group leader
“We have been working together with ProteoGenix since 2020. Using phage display, they helped our team to develop several antibodies with effective blocking effects. We are pleased with their services and look forward to continue working together with them as we advance our research and bring the biologics to the clinical stage.”
Birmingham University, UK
Dr. Julie Rayes, Associate Professor
“I contacted ProteoGenix regarding the generation of monoclonal antibodies for the detection of a chemokine. ProteoGenix generated for us multiple monoclonal antibodies to detect the chemokine by ELISA, western blot and to test these antibodies in functional assays. They provided an excellent service, with regular updates, quick response to our queries and an excellent delivery of the product. I recommend their service for their efficacy and professionalism.”
Brown University, USA
Prof Jonathan Kurtis, MD, PhD, Chair, Department of Pathology and Laboratory Medicine
“I requested ProteoGenix’s services for the generation of antibodies against a malarial protein by phage display. Their naive human library, which is comprised of 368 donors, is a unique resource which was one of the criteria I used to select their company. They optimized their standard screening strategy to be able to identify two specific clones, that they then expressed with very high yields in their proprietary XtenCHO™ cell line. I highly appreciated their level of expertise and their commitment to go beyond expectations, and I would recommend them for their reactivity and the high quality of their services.”
Telum Therapeutics, Spain
Verónica Alcolea, Development Manager
“We are thrilled with the success we’ve achieved through our collaboration with ProteoGenix in developing monoclonal antibodies targeting our protein. The antibodies they produced were not only highly selective but also demonstrated exceptional affinity for our target, significantly advancing our research.
ProteoGenix impressed us with their efficiency and speed throughout the process. Their commitment to providing excellent customer service made our experience even better, as they were always available to address our questions and concerns.
We highly recommend ProteoGenix to anyone in need of high-quality antibody development.”
Canopy Immuno-Therapeutics, Israel
Dr. Galit Denkberg, Vice-President Discovery
“We contacted ProteoGenix to develop repertoires of specific antibodies against three antigens sharing high homology. As determined by ELISA, ProteoGenix developed several specific antibodies that exhibited no cross-reactivity with the other antigens. We appreciated their proactive approach to increase our chances of success (e.g., performing fusions at their own risks). We are satisfied with the services of the company.”
Explore the latest advancements, expert insights, news shaping antibody research. From scientific publications and breakthrough innovations to upcoming webinars and exclusive content, stay informed and inspired. Gain the knowledge and tools you need to accelerate your discoveries.
Upcoming webinar
Bridging Artificial Intelligence and Wet Lab : a new era in Antibody Development
June 19, 2025 – 5pm CET
Publication
H Cerutti et al., Large scale production and characterization of SARS-CoV-2 whole antigen for serological test development. J Clin Lab Anal 35, (4) 23735 (2021).
Webinar Replay
Proven strategies to boost your antibody expression
Looking for effective strategies to optimize your transient protein & antibody production?
Video
Q&A with experts:
XtenCHO™ Race, the next generation mammalian transient expression system.
Whitepaper
The Ultimate Antibody Production Guide
A clear and practical overview of antibody production, revisiting the key principles behind monoclonal and polyclonal antibodies.
Video
Custom Cell Line Development
Find out why ProteoGenix is the trusted partner for custom cell line development.
Publication
M Pitaro et al., Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms. Front Immunol 15, 1520103 (2024).
Video
Inside ProteoGenix: CEO Insights
Philippe Funfrock, co-founder and CEO of ProteoGenix, shares his journey and vision for the company.
Dive into our most recent posts and discover insights, expert opinions, and breakthroughs in the world of life sciences and biotechnology.
Customers success stories
Apr 07, 2025
Antibody production
Mar 13, 2025
Antibody production
Mar 10, 2025
Need a personalized consultation or a quote ? Message us and we will get back to you in less than 48 hours.
100ug
100ug
100ug
